Oliver McCammon

Stock Analyst at LifeSci Capital

(4.73)
# 717
Out of 5,074 analysts
89
Total ratings
34.2%
Success rate
38.3%
Average return
Main Sectors:

Stocks Rated by Oliver McCammon

Faeth Therapeutics
Oct 15, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $20.10
Upside: +99.00%
Monte Rosa Therapeutics
Oct 2, 2026
Reiterated: Buy
Price Target: n/a
Current: $11.11
Upside: -
Corbus Pharmaceuticals Holdings
Sep 14, 2026
Reiterated: Buy
Price Target: $38
Current: $4.13
Upside: +820.10%
Inhibrx Biosciences
Sep 8, 2026
Reiterated: Buy
Price Target: $230
Current: $97.10
Upside: +136.87%
Candel Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $16
Current: $8.38
Upside: +90.93%
Celcuity
Aug 14, 2026
Reiterated: Buy
Price Target: $165
Current: $65.57
Upside: +151.64%
Aura Biosciences
Aug 12, 2026
Reiterated: Buy
Price Target: $23
Current: $6.46
Upside: +256.04%
Perspective Therapeutics
Aug 11, 2026
Reiterated: Buy
Price Target: $15
Current: $2.26
Upside: +563.72%
Janux Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $60
Current: $17.06
Upside: +251.70%